Searchable abstracts of presentations at key conferences in endocrinology

ea0063p346 | Thyroid 1 | ECE2019

Thyroid dysfunction in Egyptian HCV patients: prevalence and possible triggering factors

El Haddad Hemmat , Fayed Ahmed , Hussin Mervat

Introduction: The contribution of chronic hepatitis C virus (HCV) infection per se in thyroid autoimmunity and dysfunction remains controversial.Aim: To investigate the prevalence of thyroid disorders and the possible association between thyroid dysfunction and different factors in a cohort of HCV untreated patients.Material and methods: A total 1050 patients with untreated HCV infection were enrolled in this study. Thyroid functio...

ea0049ep1398 | Thyroid (non-cancer) | ECE2017

Beware a rapidly enlarging Thyroid mass- a case of Thyroid Lymphoma

Ashraff Suhel , Sharefi Ahmed Al , Nag Satyajit

Primary Thyroid Lymphoma is rare comprising less than 5% among all thyroid malignancies. It is historically associated with Hashimotos thyroiditis. It typically presents as a rapidly enlarging, painless goitre resulting in compression symptoms. Thyroid ultrasound and FNA cytology, using flow cytometry and immunohistochemistry, remain the primary modalities to confirm the presence of lymphoma. Treatment depends on the immunohistology. The prognosis is subtype depended and is ge...

ea0048p12 | Poster Presentations | SFEEU2017

Role of peri-operative psychiatric assessment and intervention in managing the obese patient presenting for bariatric surgery: A complex case of post-bariatric surgery addiction transfer

Mohamed Isra Ahmed , Waller Kathryn , McGowan Barbara

Objective: A case study that demonstrates the importance of thorough psychiatric assessment, intervention and follow-up in morbidly obese patients presenting for Bariatric surgery and risk of addiction transfer.Background: Positive correlation between psychiatric disorders and obesity is documented. Cases of addiction transfer have been reported complicating outcome post Bariatric Surgery.Case description: A 29 year old Caucasian f...

ea0044ep29 | (1) | SFEBES2016

Severe hypercalcaemia in sarcoidosis: Is Vitamin D replacement safe?

El-Laboudi Ahmed , Ramli Rozana , Hatfield Emma

Objective: To highlight the issue of vitamin D supplementation in patients with sarcoidosis.Case report: We report the case of a 66-year-old lady, who presented with one week history of general weakness, drowsiness, nausea and confusion. 6-weeks prior to presentation, she underwent right-sided intra-medullary nail insertion for a traumatic femur fracture, whilst abroad. Her past medical history includes stage IV pulmonary sarcoidosis, pulmonary hypertens...

ea0059p046 | Bone and calcium | SFEBES2018

Role of Ultrasound Neck (US), sestamibi Scintigraphy and Multidisciplinary team (MDT) discussion prior to intervention in the localization of parathyroid lesion

Ahmed Syed , Shakeel Majeed Muhammad , Till David

Background: Primary hyperparathyroidism is an endocrine disorder characterized by autonomous production of parathyroid hormone (PTH) results in the derangement of calcium metabolism. Imaging modalities used to localize includes technetium-99m sestamibi, sestamibi-single photon emission computed tomography (SPECT), SPECT-CT fusion, ultrasound Neck and Four dimensional computed tomography (4D-CT). Sestamibi scintigraphy combined with sestamibi single photon emission computed tom...

ea0059ep96 | Reproduction | SFEBES2018

Unusual Cause of Severe Hyponatraemia

Hanafy Ahmed , Holmes Simon , Rajeswaran Chinnadorai

Introduction: Testosterone replacement therapy is the standard treatment for hypogonadism. However, there are also serious side effects which clinicians should be aware of. Here we present a case of unusual side effect related to testosterone therapy.Case history: A 90 year-old gentleman attended A&E with gradually worsening confusion and dyspnoea. His breathing had deteriorated in the last week with marked decrease in exercise tolerance. Investigati...

ea0038p28 | Clinical biochemistry | SFEBES2015

Where are the endocrinologists?

Broughton Chloe , Ahmed Shaza , Bhattacharya Beas

Introduction: Hyponatraemia is defined as serum sodium concentration <135 mmol/l. It is the most common electrolyte disorder encountered in clinical practise. It is associated with an increase in mortality and length of stay, independent of diagnosis and clinical variables. Despite this it is often inadequately investigated and poorly managed. As a number of endocrine conditions can cause hyponatraemia, endocrinologists often have the necessary clinical skills and expertis...

ea0038p36 | Clinical biochemistry | SFEBES2015

Inhibiting more than the proton pump

Broughton Chloe , Ahmed Shaza , Bhattacharya Beas

Introduction: Hyponatraemia is defined as serum sodium concentration <135 mmol/l. It is the most common electrolyte disorder encountered in clinical practise (1). Proton pump inhibitors (PPI’s) are commonly prescribed in the UK, and the indication and duration of treatment is often not reviewed.Methods: A retrospective audit was performed of patients admitted to The Great Western Hospital (GWH) with a serum sodium of 127 mmol/l or less on admiss...

ea0038p62 | Clinical practice/governance and case reports | SFEBES2015

Nothing to ‘sea’ here: turning a blind eye to hyponatraemia

Broughton Chloe , Ahmed Shaza , Bhattacharya Beas

Introduction: Hyponatraemia is defined as serum sodium concentration <135 mmol/l. It is the most common electrolyte disorder encountered in clinical practise. It is associated with an increase in mortality and length of stay, independent of diagnosis and clinical variables. Despite this it is often inadequately investigated and poorly managed.Methods: A retrospective audit was performed of patients admitted to The Great Western Hospital (GWH) serum s...

ea0038p86 | Clinical practice/governance and case reports | SFEBES2015

Four years of tolvaptan: experience from two large teaching hospitals

Follows Joseph , Iqbal Ahmed , Allahabadia Amit

Introduction: Hyponatraemia is a common cause of morbidity and mortality affecting 15–28% of inpatients. Tolvaptan is a competitive vasopressin 2 antagonist licensed to treat hyponatraemia secondary to the syndrome of inappropriate anti-diuretic hormone secretion (SIADH). There has been concern that tolvaptan treatment may lead to rapid overcorrection of sodium in a minority of patients, thus potentially leading to osmotic demyelination syndrome.Met...